CompletedNCT01500694
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Medication studyAges 6–17Multiple countriesADHD
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Graz, Austria · Vienna, Austria and 52 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: March 20, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 215
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01500694
- Official title
Show the full official title
A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316
Recruitment & locations
CompletedGraz, Austria · Vienna, Austria · Hoboken, Belgium
51 more locations
- Namur, Belgium
- Oostham, Belgium
- Vlezenbeek, Belgium
- Amiens, France
- Bordeaux, France
- Montpellier, France
- Achim, Germany
- Berlin, Germany
- Dorsten, Germany
- Dresden, Germany
- Fulda, Germany
- Hagen, Germany
- Hamburg, Germany
- Hüttenberg, Germany
- Jena, Germany
- Mainz, Germany
- München, Germany
- Schwerin, Germany
- Ulm, Germany
- Crumlin, Ireland
- Catania, Italy
- Milan, Italy
- Padova, Italy
- Pisa, Italy
- Verona, Italy
- Almere Stad, Netherlands
- Heerlen, Netherlands
- Gdansk, Poland
- Torun, Poland
- Wroclaw, Poland
- Timișoara, Romania
- Bucharest, Romania
- Iași, Romania
- Terrassa, Spain
- Barcelona, Spain
- Madrid, Spain
- Palma de Mallorca, Spain
- Santander, Spain
- Valencia, Spain
- Gothenburg, Sweden
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- Stevenage, United Kingdom
- Welwyn Garden City, United Kingdom
- West Derby, United Kingdom
- Norwich, United Kingdom
- Sheffield, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Extended-release Guanfacine HCl (Intuniv, SPD503).
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...